During a six-month chronic oral toxicity study of Sprague-Dawley rats, researchers found that Caralluma fimbriata produced no deaths or treatment-related toxicities at three doses (100, 300, and 1000 mg/kg body weight). Additionally, no external, visceral, or skeletal fetal abnormalities were observed following a prenatal developmental toxicity study up to the maximum dose tested.
Published in the International Journal of Toxicology, the study was conducted by INTOX Pvt Ltd.
“These assessments are great news for consumers looking for safe weight management support,” said Dr. Paul Clayton, chief scientific advisor at Gencor. “Together with its scientifically validated ability to reduce fat and suppress appetite, Caralluma fimbriata offers both safety and efficacy.”
Previously, two double blind, placebo-controlled clinical trials found statistically significant decreases in waist circumference in experimental groups taking Caralluma fimbriata compared to placebo groups.
Since 2006, Gencor has offered a patented extract of Caralluma fimbriata as an appetite suppressant under the brand name Slimaluma. Versatile for delivering a wide range of tastes and textures, Slimaluma can be used in beverages, smoothies, capsules, tablets, chocolates and meal replacements. Slimaluma is self-affirmed GRAS, Kosher and Halal, and available certified Organic.
Gencor (GE Nutrients, Inc.) supplies value-added, science-driven ingredients that are designed to improve quality of life for consumers in a broad range of life stages. Rooted in Ayurvedic tradition, Gencor specializes in herbal extracts manufactured under GMP compliance. Gencor markets specialized ingredients in over 32 countries worldwide.